RxDoctor Payments Data

Jun Yang, MD

Internal Medicine · Flushing, NYNPI 1184891848

Payments from drug & device makers

$6,019in general payments, 2019–2025

Across 278 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • AstraZeneca$614
  • Amarin Pharma, Inc.$538
  • AbbVie$530
  • Amgen$459
  • Exact Sciences$338
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$6,011100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,019 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$5,406
Medicare patients
21
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl1,958$693,296
JanumetSitagliptin Phos/Metformin Hcl440$251,547
VemlidyTenofovir Alafenamide158$233,934
Diclofenac Sodium573$173,802
FarxigaDapagliflozin Propanediol263$156,200
JardianceEmpagliflozin206$130,150
Lactulose57$119,801
JanuviaSitagliptin Phosphate159$95,741
TradjentaLinagliptin102$57,735
Diclofenac Epolamine126$50,098
Omega-3 Acid Ethyl Esters430$36,347
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$28,715
ShingrixVaricella-Zoster Ge/As01b/Pf167$26,113
XareltoRivaroxaban45$25,334
DapagliflozinDapagliflozin Propanediol50$24,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Janumet Xr$149$368,183660 claims
GileadVemlidy$2,533$233,934158 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$21$209,422355 claims
AstraZenecaFarxiga, Breztri Aerosphere$614$184,914306 claims
GSKShingrix, Arnuity Ellipta$71$32,132197 claims
AbbVieLinzess, Creon, Synthroid$530$30,188184 claims
PfizerEliquis$25$15,43632 claims
NovartisEntresto$31$14,77021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →